Human antibody Fc deamidation in vivo

Biologicals

Volumn 37, Issue 5, 2009, Pages 313-322

  Liu, Y Diana ^a   van Enk, Jian Zhang ^a   Flynn, Gregory C ^a  

^a AMGEN INC   (United States)

Author keywords

Critical quality attribute; Deamidation; Posttranslational modification

Indexed keywords

ASPARAGINE; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT IMMUNOGLOBULIN G2 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEAMINATION; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOGLOBULIN BLOOD LEVEL; ISOMERIZATION; MALE; NORMAL HUMAN; PEPTIDE MAPPING; PH; PRIORITY JOURNAL; PROTEIN PROCESSING; SINGLE DRUG DOSE; TEMPERATURE;

AMIDES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MODELS, MOLECULAR; PROTEIN PROCESSING, POST-TRANSLATIONAL; TANDEM MASS SPECTROMETRY;

EID: 69649088633     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.06.001     Document Type: Article

References (22)

1. Meinwald Y.C., Stimson E.R., and Scheraga H.A. Deamidation of the asparaginyl-glycyl sequence. Int J Pept Protein Res 28 (1986) 79-84
2. Geiger T., and Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262 (1987) 785-794
3. Capasso S., Mazzarella L., Sica F., and Zagari A. Deamidation via cyclic imide in asparaginyl peptides. Pept Res 2 (1989) 195-200
4. Tyler-Cross R., and Schirch V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 266 (1991) 22549-22556
5. Robinson N.E., and Robinson A.B. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci U S A 98 (2001) 4367-4372
6. Robinson N.E., Robinson Z.W., Robinson B.R., Robinson A.L., Robinson J.A., Robinson M.L., et al. Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J Pept Res 63 (2004) 426-436
7. Robinson N.E., and Robinson A.B. Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. J Pept Res 63 (2004) 437-448
8. Huang L., Lu J., Wroblewski V.J., Beals J.M., and Riggin R.M. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77 (2005) 1432-1439
9. Harris R.J., Kabakoff B., Macchi F.D., Shen F.J., Kwong M., Andya J.D., et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752 (2001) 233-245
10. Keck R., Nayak N., Lerner L., Raju S., Ma S., Schreitmueller T., et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals 36 (2008) 49-60
11. Liu Y.D., Chen X., van Enk J.Z., Plant M., Dillon T.M., and Flynn G.C. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 283 (2008) 29266-29272
12. Zhang Z. De novo peptide sequencing based on a divide-and-conquer algorithm and peptide tandem spectrum simulation. Anal Chem 76 (2004) 6374-6383
13. Robinson N.E. Protein deamidation. Proc Natl Acad Sci U S A 99 (2002) 5283-5288
14. Xiao G., and Bondarenko P.V. Identification and quantification of degradations in the Asp-Asp motifs of a recombinant monoclonal antibody. J Pharm Biomed Anal 47 (2008) 23-30
15. Harris L.J., Skaletsky E., and McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275 (1998) 861-872
16. Nonaka Y., Aizawa T., Akieda D., Yasui M., Watanabe M., Watanabe N., et al. Spontaneous asparaginyl deamidation of canine milk lysozyme under mild conditions. Proteins 72 (2008) 313-322
17. Chen X., Liu Y.D., and Flynn G.C. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19 (2009) 240-249
18. Vlug A., Nieuwenhuys E.J., van Eijk R.V., Geertzen H.G., and van Houte A.J. Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris) 52 (1994) 561-567
19. Alyanakian M.A., Bernatowska E., Scherrmann J.M., Aucouturier P., and Poplavsky J.L. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 84 (2003) 188-192
20. Out T.A., McDonald J.R., Woldhuis-Kant J., and Nieuwenhuys E.J. The effect of reduction of IgM on the quantitative determination of IgM by radial immunodiffusion and turbidimetry. Clin Chim Acta 144 (1984) 115-126
21. Yoo E.M., Wims L.A., Chan L.A., and Morrison S.L. Human IgG2 can form covalent dimers. J Immunol 170 (2003) 3134-3138
22. Wakankar A.A., and Borchardt R.T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 95 (2006) 2321-2336